Zai Lab Limited (ZLAB) Revenue History
Annual and quarterly revenue from 2015 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ZLAB Revenue Growth
Revenue Breakdown (FY 2025)
ZLAB's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
ZLAB Revenue Analysis (2015–2025)
As of May 6, 2026, Zai Lab Limited (ZLAB) generated trailing twelve-month (TTM) revenue of $460.2 million, reflecting strong growth of +17.0% year-over-year. The most recent quarter (Q4 2025) recorded $127.6 million in revenue, up 9.9% sequentially.
Looking at the longer-term picture, ZLAB's 5-year compound annual growth rate (CAGR) stands at +56.5%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $460.2 million in 2025, representing a new all-time high.
Revenue diversification analysis shows ZLAB's business is primarily driven by Zejula (57%), Nuzyra (18%), and Optune (14%). With over half of revenue concentrated in Zejula, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including LEGN (+64.2% YoY), ZYME (+38.9% YoY), and CAN (+96.8% YoY), ZLAB has underperformed the peer group in terms of revenue growth. Compare ZLAB vs LEGN →
ZLAB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ZLABCurrent | $460M | +17.0% | +56.5% | -49.9% | |
 LEGN | $1.0B | +64.2% | +68.9% | -13.3% | |
 ZYME | $106M | +38.9% | +22.2% | -87.3% | |
 CAN | $530M | +96.8% | +50.5% | -21.2% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% |
ZLAB Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $460.2M | +15.3% | $269.6M | 58.6% | $-229,434,000 | -49.9% |
| 2024 | $399.0M | +49.6% | $251.1M | 62.9% | $-282,117,000 | -70.7% |
| 2023 | $266.7M | +24.0% | $170.9M | 64.1% | $-366,573,000 | -137.4% |
| 2022 | $215.0M | +49.0% | $141.0M | 65.6% | $-404,357,000 | -188.0% |
| 2021 | $144.3M | +194.8% | $92.1M | 63.8% | $-700,064,000 | -485.1% |
| 2020 | $49.0M | +277.0% | $-190,489,000 | -389.1% | $-301,801,000 | -616.4% |
| 2019 | $13.0M | +9930.6% | $9.2M | 71.1% | $-203,195,939 | -1564.9% |
| 2018 | $129K | - | $86K | 66.3% | $-141,768,082 | -109514.0% |
| 2017 | $0 | - | $0 | - | $-51,391,036 | - |
| 2016 | $0 | - | $0 | - | $-38,529,301 | - |
See ZLAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ZLAB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ZLAB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonZLAB — Frequently Asked Questions
Quick answers to the most common questions about buying ZLAB stock.
Is ZLAB's revenue growth accelerating or slowing?
ZLAB revenue is accelerating at +17.0% year-over-year, exceeding the 5-year CAGR of +56.5%. TTM revenue reached $460M. Growth momentum has increased versus prior periods.
What is ZLAB's long-term revenue growth rate?
Zai Lab Limited's 5-year revenue CAGR of +56.5% reflects the sustained expansion pattern. Current YoY growth of +17.0% is above this long-term average.
How is ZLAB's revenue distributed by segment?
ZLAB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2025 are available for download. Segment mix reveals concentration and diversification trends.